Fabtech Technologies Limited reported a 25.7% year-on-year increase in standalone revenue to ₹410.77 Cr for the year ended March 31, 2026, while announcing new strategic initiatives including a ₹49.00–52.00 Cr North Africa veterinary facility and an EU GMP plant aimed at supporting exports. Operational profit rose 17% to ₹36.60 Cr, and the company maintained a confirmed order book of ₹900+ Cr, providing strong revenue visibility for coming periods. The firm is targeting standalone revenue of ₹500 Cr and a profit after tax (PAT) of ₹45 Cr for FY27, driven by a robust enquiry pipeline and strategic expansion into premium markets.

Key Financial Metrics

The following table summarises Fabtech Technologies' latest financial performance and near-term targets:

New Strategic Wins and Expansion Projects

Fabtech Technologies has identified a North Africa veterinary facility valued at ₹49.00–52.00 Cr as a key near-term target, adding to its pipeline of international projects. The company is also pursuing an EU GMP plant designed to support exports, which is expected to strengthen its brand presence and margins in regulated markets. These initiatives complement recent strategic wins, including a USD 7.05M oral solid dosage facility in West Africa and a USD 7.8M animal vaccine project in Saudi Arabia, underscoring the company's growing footprint in specialised pharmaceutical and veterinary infrastructure.

Growth Strategy and Market Focus

The company's growth strategy focuses on three primary levers: a European acquisition to strengthen brand presence and margins, joint ventures in Saudi Arabia and Africa, and improved working-capital strength to enable faster project acquisition. Management highlighted that 78% of revenue is derived from MENA, GCC & ECO Zone markets, supported by an asset-light model that scales through in-house arms and strategic partners. By securing domestic status in the UAE and Saudi Arabia, the company unlocks natural tax advantages and eligibility for local-content tenders.

Margin Expansion Roadmap

Fabtech Technologies is executing a margin expansion roadmap targeting a PAT margin increase from the current 8–9% to 11–13%. This will be achieved through localisation benefits, alternative sourcing, and taking on the pre-engineered building (PEB) scope to control civil works and project timelines. The company has delivered 500+ projects across 62+ countries, establishing a reference-led moat with landmark facilities such as the largest IV solution facility in Saudi Arabia and the first biosimilars facility in Algeria.

Long-Term Vision

The investor presentation, submitted to exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, outlined a 15-year structural opportunity driven by regional medicinal sovereignty. The company's long-term vision, FTL 2030, aims to climb the value curve into advanced-technology facilities including medical diagnostics, vaccines, biotech, and cell & gene therapy. The disclosure was made by Hemant Mohan Anavkar, Executive Director.

Fabtech Technologies confirmed that its promoters and promoter group did not create any encumbrance, directly or indirectly, over the shares held by them during the financial year ended March 31, 2026. This disclosure ensures that the shareholding structure remains free from pledged assets, which is a key indicator of financial stability for investors. The declaration was submitted to the stock exchanges in compliance with regulatory requirements.

The filing was made by Aasif Ahsan Khan on behalf of the Promoter and Promoter Group of Fabtech Technologies to the National Stock Exchange of India Limited and BSE Limited. The submission was made under Regulation 31(4) and 31(5) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The document was digitally signed on April 08, 2026.

The disclosure covers a comprehensive list of 66 entities, including individuals and corporate entities, classified as either Promoters or members of the Promoter Group. The list includes key individuals such as Aarif Ahsan Khan, Hemant Mohan Anavkar, and Manisha Hemant Anavkar. Corporate entities within the group include Fabtech Turnkey Projects LLP, F Plus Healthcare Technologies Private Limited, and Fabtech Technologies Cleanrooms Limited.

The complete list of promoters and promoter group members submitted to the exchanges is detailed below:

The Audit Committee of Fabtech Technologies Limited was also marked as a recipient on the disclosure. The company was formerly known as Fabtech Technologies Private Limited.